Splicing modifier intended to deal with SMA because of mutations in chromosome 5q that produce survival motor neuron (SMN) protein deficiency. Evrysdi is administered daily at home in liquid variety by mouth or by feeding tube. Risdiplam, an SMN2 splicing modifier, is currently the only real orally administered drug accredited https://ericy964oux7.corpfinwiki.com/user